Lomustine and Bevacizumab in Progressive Glioblastoma

• Published in: The New England journal of medicine Vol. 377; no. 20; pp. 1954 - 1963
• Main Authors: Wick, Wolfgang, Gorlia, Thierry, Bendszus, Martin, Taphoorn, Martin, Sahm, Felix, Harting, Inga, Brandes, Alba A, Taal, Walter, Domont, Julien, Idbaih, Ahmed, Campone, Mario, Clement, Paul M, Stupp, Roger, Fabbro, Michel, Le Rhun, Emilie, Dubois, Francois, Weller, Michael, von Deimling, Andreas, Golfinopoulos, Vassilis, Bromberg, Jacoline C, Platten, Michael, Klein, Martin, van den Bent, Martin J
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 16-11-2017
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating - administration & dosage; Antineoplastic Agents, Alkylating - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bevacizumab; Bevacizumab - administration & dosage; Bevacizumab - adverse effects; Brain cancer; Brain Neoplasms - drug therapy; Brain Neoplasms - mortality; Brain Neoplasms - radiotherapy; Brain research; Cancer; Cancer therapies; Chemoradiotherapy; Clinical trials; Cognition; Disease-Free Survival; DNA methylation; DNA methyltransferase; Female; Glioblastoma; Glioblastoma - drug therapy; Glioblastoma - mortality; Glioblastoma - radiotherapy; Humans; Immunotherapy; Intention to Treat Analysis; Kaplan-Meier Estimate; Life Sciences; Lomustine - administration & dosage; Lomustine - adverse effects; Male; Medical research; Methylguanine; Middle Aged; Monoclonal antibodies; NMR; Nuclear magnetic resonance; O6-methylguanine-DNA methyltransferase; Oncology; Quality of life; Survival; Targeted cancer therapy
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa1707358

The addition of bevacizumab to lomustine in patients with recurrent glioblastoma failed to increase overall survival but was associated with a small increase in progression-free survival.